Benralizumab Delivers Faster Nasal Relief in Patients With Dual Airway Disease
In patients living with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps, benralizumab did not produce a uniform response across every symptom domain. Improvement arrived first in the nose and face, while functional and emotional burden eased more slowly over time. The pattern matters because it reflects how one biologic can deplete eosinophils quickly yet still leave patients waiting for the full lived experience of recovery to catch up.
The BANDOR study followed a real-world cohort with this dual-airway phenotype over 18 months and found durable benefit in those who stayed on therapy. The analysis centered on how symptoms moved over time rather than on a single endpoint snapshot, which is often where clinical trials miss the nuance of chronic inflammatory disease. In practice, that approach exposed a split between early and late recovery, with baseline disease burden helping separate the two groups.
Distinct Symptom Domains Did Not Recover at the Same Speed
The sinonasal symptom profile improved in a staggered way. Nasal and physical complaints improved within the first months of treatment, even though earlier randomized studies in nasal polyposis had produced inconsistent results. Functional and emotional domains took longer to reach a stable plateau, suggesting that patients can feel the first benefit before they feel fully restored.
This is biologically plausible. Benralizumab targets IL-5 receptor alpha on eosinophils and basophils and drives near-complete eosinophil depletion through antibody-dependent cell-mediated cytotoxicity. When eosinophilic inflammation is the engine of mucosal edema, obstruction, and tissue injury, symptom relief should begin where inflammatory load is most directly translated into physical blockage and drainage. Emotional recovery is slower because it depends not only on inflammation control but also on the return of sleep quality, smell, daily function, and confidence in symptom stability.
One practical consequence is immediate. Patients may report early nasal relief while still describing lingering fatigue, frustration, or reduced activity.
Higher Baseline Eosinophils Marked the Fastest Responders
Early responders stood out at baseline. They had a significantly higher eosinophil count, with a median of 885 cells per microliter compared with 530 cells per microliter in late responders, and they also began with greater bronchial obstruction. In other words, the patients with the most visible eosinophilic burden and the most compromised airways were the ones most likely to improve quickly.
This finding fits the drug’s mechanism. A stronger eosinophilic signature gives benralizumab more target cells to eliminate, and a more inflammatory phenotype may create a clearer therapeutic signal once that cell population disappears. The study therefore points to baseline eosinophilia as a practical marker of speed of response, not just likelihood of response.
The lung function story was steadier than the symptom story. FEV1 remained functionally stable throughout observation, while oral corticosteroid use declined and stayed reduced over time. Stability can matter as much as improvement in severe asthma, especially in patients who have already spent years cycling through exacerbations, rescue medication, and steroid exposure.
A Retrospective Cohort Captured Real-World Persistence Over 18 Months
The study used a retrospective, multicenter design across Italian specialist centers and examined adults with a United Airways Disease phenotype. A total of 54 patients were screened, 13 were excluded or discontinued therapy before 18 months, and 41 patients completed the full observation window. The final cohort therefore reflects persistent users rather than a broad all-comers population, which makes the response signal cleaner but also narrower.
That design choice has clinical consequences. Because only patients who maintained continuous treatment were analyzed, the results describe the group that stayed engaged with benralizumab long enough to reach a durable state of control. This is the population most relevant to long-term adherence decisions in specialty practice, but it is not the same as a trial cohort enriched for early discontinuation or nonresponse.
The inclusion framework required severe eosinophilic asthma and CRSwNP confirmed by standard criteria, and patients were followed across baseline and repeated time points at 3, 6, 12, and 18 months. That longitudinal structure allowed the investigators to track when each domain changed, not simply whether it changed.
Why the Real-World Signal Looked Better Than Trial Endpoints
Randomized trials in nasal polyposis have not consistently matched the level of benefit seen in severe asthma. Real-world observation in BANDOR suggests one reason: the response may be concentrated in a high-burden eosinophilic phenotype that is diluted inside broader trial populations. Patients with both severe asthma and nasal polyps may be more likely to show a visible treatment effect because they carry a system-wide type 2 inflammatory load that is easier to interrupt.
The biology supports this interpretation. In united airway disease, the nose and bronchi behave like connected inflammatory compartments, so lowering eosinophil activity in one part of the respiratory tract can produce synchronized improvement elsewhere. Even so, the recovery curve is not uniform. Physical symptoms fall first, then function, then the emotional weight of chronic disease.
This matters at the bedside when expectations are being set. A patient who feels better in the first months may still need time before the full burden of disease feels meaningfully lighter.
What This Means for Severe Eosinophilic Asthma With Nasal Polyps
BANDOR positions benralizumab as a therapy capable of producing durable remission in a selected subset of adherent patients with dual airway disease. The strongest predictor of rapid improvement was a high initial eosinophilic burden, with worse baseline bronchial obstruction adding to that signal. For clinicians, the message is not that every patient will improve in the same way, but that timing, domain, and baseline biology all influence how treatment success appears in real practice.
The study also reinforces the value of tracking sinonasal symptoms with more granularity than a single composite score. When nasal obstruction, physical discomfort, function, and emotional impact move on different schedules, the therapeutic story becomes more useful at the individual level. Patients do not experience remission as a laboratory result.
They experience it as the return of airflow, sleep, smell, and daily stability over months.
The analysis is still limited by its retrospective design and by the fact that only patients who maintained benralizumab for 18 months were included in the final cohort. Earlier discontinuations, including those linked to lack of efficacy, were not part of the long-term outcome assessment. What remains unknown is how broadly these findings apply to less selected patients, especially those with lower eosinophil counts or a weaker type 2 signal at baseline.